These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16596227)

  • 21. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in the RAD51 gene and familial breast cancer.
    Lose F; Lovelock P; Chenevix-Trench G; Mann GJ; Pupo GM; Spurdle AB;
    Breast Cancer Res; 2006; 8(3):R26. PubMed ID: 16762046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated levels of Rad51 recombination protein in tumor cells.
    Raderschall E; Stout K; Freier S; Suckow V; Schweiger S; Haaf T
    Cancer Res; 2002 Jan; 62(1):219-25. PubMed ID: 11782381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
    Kiss-László Z; Nagy B; Thurzó L; Szabó J
    Magy Onkol; 2006; 50(1):33-7. PubMed ID: 16617381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
    Salama JK; Stenson KM; List MA; Mell LK; Maccracken E; Cohen EE; Blair E; Vokes EE; Haraf DJ
    Arch Otolaryngol Head Neck Surg; 2008 Oct; 134(10):1060-5. PubMed ID: 18936351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation.
    Vergeer MR; Doornaert P; Leemans CR; Buter J; Slotman BJ; Langendijk JA
    Radiother Oncol; 2006 Apr; 79(1):39-44. PubMed ID: 16632006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer stem cells in head and neck squamous cell cancer.
    Prince ME; Ailles LE
    J Clin Oncol; 2008 Jun; 26(17):2871-5. PubMed ID: 18539966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors--long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin.
    Villar A; Martinez JC; de Serdio JL
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1382-8. PubMed ID: 18037586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study.
    Thariat J; Ahamad A; El-Naggar AK; Williams MD; Holsinger FC; Glisson BS; Allen PK; Morrison WH; Weber RS; Ang KK; Garden AS
    Cancer; 2008 Jun; 112(12):2698-709. PubMed ID: 18429002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer.
    Krupa R; Synowiec E; Pawlowska E; Morawiec Z; Sobczuk A; Zadrozny M; Wozniak K; Blasiak J
    Exp Mol Pathol; 2009 Aug; 87(1):32-5. PubMed ID: 19426727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
    Finnegan V; Parsons JT; Greene BD; Sharma V
    Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies.
    Elting LS; Cooksley CD; Chambers MS; Garden AS
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1110-20. PubMed ID: 17398022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
    Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck.
    Fortin A; Caouette R; Wang CS; Vigneault E
    Am J Clin Oncol; 2008 Aug; 31(4):379-83. PubMed ID: 18845998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
    Milano MT; Vokes EE; Kao J; Jackson W; List MA; Stenson KM; Witt ME; Dekker A; MacCracken E; Garofalo MC; Chmura SJ; Weichselbaum RR; Haraf DJ
    Int J Oncol; 2006 May; 28(5):1141-51. PubMed ID: 16596230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
    Cho YH; Lee SH; Kim DW; Wu HG; Hah JH; Rhee CS; Sung MW; Kim KH; Heo DS
    Head Neck; 2008 Mar; 30(3):346-50. PubMed ID: 17972310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
    Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
    Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.